NEW YORK (GenomeWeb news) – The Burnham Institute for Medical Research will conduct research on oncology drug targets and cancer biology as part of efforts to develop personalized medical approaches to cancer for the National Cancer Institute, Burnham said on Monday.

NCI has named Burnham a Comprehensive Center in its Chemical Biology Consortium, which is a network of molecular oncologists, chemical biologists, and chemical screening centers, and it will conduct the work at the Burnham campuses in La Jolla, Calif., and in Orlando, Fla.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Oct
12
Sponsored by
PierianDx

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers. 

Oct
17
Sponsored by
Cofactor Genomics

This webinar will discuss the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.